ACCP Annual Meeting Invited Keynote

Steven D. Gore, MD – Professor of Medicine (Hematology) & Director, Hematologic Malignancies, Yale Cancer Ctr
20 years of ‘Epigenetic’ Cancer Therapy - Who are we Fooling?

Dr. Steven Gore joined the Yale Cancer Ctr as Professor of Medicine (Hematology) & Director of Hematologic Malignancies in 2013 following 23 years on the faculty of the Sidney Kimmel Comprehensive Cancer Ctr at Johns Hopkins in the Div of Hematologic Malignancies. He has been recognized as a leader in clinical and translational research in myeloid malignancies, especially myelodysplastic syndrome and clinical applications of epigenetics in cancer therapeutics. Dr. Gore is co-chair of the Leukemia Steering Committee for the National Clinical Trials Network and a member of the Leukemia Core Committee and Leukemia Laboratory Committee of the Eastern Cooperative Oncology Group. He has developed several National Cancer Inst- and pharma-sponsored early-phase trials with translational endpoints, as well as multicenter and cooperative group protocols in myelodysplastic syndrome, including the first randomized trial comparing the impact of the addition of a histone deacetylase inhibitor to a DNA methyltransferase inhibitor in myelodysplastic syndrome. Dr. Gore has chaired eight biannual int'l workshops on the Clinical Translation of Epigenetic Therapy in Cancer Therapeutics. He also serves on the External Advisory Board of the Univ of Chicago Comprehensive Cancer Ctr and has served on advisory boards and response adjudicating committees for a variety of pharma companies. See Dr. Gore's CV.